Journal Article

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

Delbove, Agathe, Valour, Florent, Lê, Minh-Patrick, Egle, Alexander, Cazanave, Charles, Mercier, Noémie, Yazdanpanah, Yazdan, Gallien, Sébastien, Kimmoun, Antoine, Diallo, Alpha, Laine, Fabrice, Ader, Florence, Costagliola, Dominique, Gaci, Rostane, Greil, Richard, Chabartier, Cyrille, Bouscambert-Duchamp, Maude, Boutoille, David, Bruel, Cédric, Lefevre, Benjamin, Fraipont, Vincent, Epaulard, Olivier, Le Tulzo, Yves, Altdorfer, Antoine, Perpoint, Thomas, Roncon-Albuquerque, Roberto, Ait-Oufella, Hafid, Mekontso-Dessap, Armand, Gaborit, Benjamin, Courjon, Johan, Revest, Matthieu, Ruch, Yvon, Lanoix, Jean-Philippe, Epelboin, Loïc, Benezit, François, Wattecamps, Guilhem, Pilmis, Benoît, Lebeaux, David, Leroy, Sylvie, Burdet, Charles, Marquette, Charles-Hugo, Lina, Bruno, Martinot, Martin, Terzi, Nicolas, Belkhir, Leila, Chirouze, Catherine, Verschelden, Gil, Clere-Jehl, Raphaël, Gaymard, Alexandre, Sayre, Naomi, Braz, Sandra, Ficko, Cécile, Pourcher, Valérie, Bounes-Vardon, Fanny, Gousseff, Marie, Ferry, Tristan, Timsit, Jean-François, Mourvilliers, Bruno, Reuter, Jean, Berna, Marc, Bouadma, Lila, Ferreira R

2022

Overview

Eligible participants were adults (aged ≥18 years) who were admitted to hospital with a positive PCR test for SARS-CoV-2 (<72 h before randomisation) and also had pulmonary rales or crackles with a peripheral oxygen saturation of 94% or less or required supplemental oxygen. Similar to findings from preliminary analyses, participants from the remdesivir group who were not on mechanical ventilation or ECMO when they were randomly assigned to a treatment group (n=692) had a significantly longer time to the composite endpoint of new mechanical ventilation, ECMO, or death in the 29 days following randomisation than did the control group (cumulative incidence in the remdesivir group was 58 [17%] of 343 participants vs 88 [25%] of 349 in the control group; adjusted hazard ratio [HR] 0·63 [95% CI 0·45–0·88]; p=0·010). In non-prespecified analyses, this effect was significant in participants with severe disease when they were randomly assigned to a treatment group (cumulative incidence in the remdesivir group 25 [29%] of 87 vs 47 [50%] of 94 in the control group; unadjusted HR 0·49 [95% CI 0·30–0·80]; p=0·0040) but not in those with moderate disease (33 (13%) of 256 vs 41 (16%) of 255; 0·79 [0·50–1·25]; p=0·31).

• Publisher: Elsevier Ltd,Elsevier Limited,New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001
• Subject: Adenosine Monophosphate - analogs & derivatives / Adenosine Monophosphate - therapeutic use / Alanine - analogs & derivatives / Alanine - therapeutic use / Clinical Trials as Topic / Coronaviruses / Correspondence / COVID-19 / COVID-19 - drug therapy / Hospitalization / Hospitals / Humans / Infectious diseases / Life Sciences / Mechanical ventilation / Mortality / Oxygen / Oxygen content / Randomization / Severe acute respiratory syndrome coronavirus 2 / Ventilation